Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.81 |
| ▸ | PLK4 | O00444 | 1/20 | 0.73 |
| ▸ | GAK | O14976 | 1/20 | 0.73 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.73 |
| ▸ | JAK2 | O60674 | 1/20 | 0.73 |
| ▸ | FLT3 | P36888 | 1/20 | 0.73 |
| ▸ | BLK | P51451 | 1/20 | 0.73 |
| ▸ | BMX | P51813 | 1/20 | 0.73 |
| ▸ | JAK3 | P52333 | 1/20 | 0.73 |
| ▸ | CTSC | P53634 | 1/20 | 0.73 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.73 |
| ▸ | BTK | Q06187 | 1/20 | 0.73 |
| ▸ | ITK | Q08881 | 1/20 | 0.73 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.73 |
| ▸ | DCLK3 | Q9C098 | 1/20 | 0.73 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.73 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.73 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.73 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893595 | 0.90 | EGFR (1.00) | EGFRPLK4GAKNUAK1JAK2 | |
| SCHEMBL24784922 | 0.89 | EGFR (0.86) | EGFRPLK4GAKNUAK1JAK2 | |
| SCHEMBL9893707 | 0.89 | EGFR (1.00) | EGFRPLK4GAKNUAK1JAK2 | |
| SCHEMBL13729999 | 0.88 | EGFR (0.75) | EGFRPLK4GAKNUAK1JAK2 | |
| SCHEMBL13729994 | 0.88 | EGFR (0.75) | EGFRPLK4GAKNUAK1JAK2 | |
| SCHEMBL13832467 | 0.87 | EGFR (0.85) | EGFRPLK4GAKNUAK1JAK2 | |
| SCHEMBL7611591 | 0.86 | EGFR (0.81) | EGFRPLK4GAKNUAK1JAK2 | |
| SCHEMBL5585393 | 0.85 | EGFR (1.00) | EGFRPLK4GAKNUAK1JAK2 | |
| SCHEMBL2718163 | 0.85 | EGFR (1.00) | EGFRPLK4GAKNUAK1JAK2 | |
| SCHEMBL9945476 | 0.85 | EGFR (0.88) | EGFRPLK4GAKNUAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834518-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | claimed |
| EP-2844642-B1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMA INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-9834518-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834518-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834518-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| EP-2704572-B1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMA INC (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2704572-B1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMA INC (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| EP-2704572-A1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD Pharmaceuticals, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2013169401-A1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| WO-2012151561-A1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | BRAF, RAF1, EGFR | EGFR 3/4885PLK4 674/4885GAK 80/4885 |
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, MKI67, ERBB2 | EGFR 1/4885PLK4 1612/4885GAK 118/4885 |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, MKI67, ERBB2 | EGFR 1/4885PLK4 1612/4885GAK 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.